Hepatic and Renal Protection During Cardiac Surgery

Anesthesiology Clinics

Volumn 26, Issue 3, 2008, Pages 565-590

  Diaz, Geraldine C ^a   Moitra, Vivek ^b   Sladen, Robert N ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANARITIDE; APROTININ; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; DILTIAZEM; DOPAMINE; FENOLDOPAM; FUROSEMIDE; GROWTH HORMONE; INSULIN; MANNITOL; MELATONIN; NESIRITIDE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PLACEBO; TACROLIMUS;

ACUTE KIDNEY FAILURE; ANESTHESIA; BLEEDING; CARDIOPULMONARY BYPASS; CHOLECYSTITIS; CHOLESTASIS; CLINICAL TRIAL; DIABETES MELLITUS; GASTROINTESTINAL HEMORRHAGE; GILBERT DISEASE; HEART FAILURE; HEART RATE; HEART SURGERY; HUMAN; HYDRATION; HYPERBILIRUBINEMIA; HYPOTENSION; HYPOVOLEMIA; INTESTINE INFARCTION; KIDNEY DISEASE; KIDNEY INJURY; LIVER FAILURE; LIVER INJURY; LIVER PROTECTION; PANCREATITIS; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; RENOVASCULAR HYPERTENSION; REVIEW; SIDE EFFECT; ULCER PERFORATION;

CARDIAC SURGICAL PROCEDURES; EVIDENCE-BASED MEDICINE; FIBROSIS; HUMANS; KIDNEY FAILURE; LIVER FAILURE; RISK FACTORS; SPLANCHNIC CIRCULATION;

EID: 50249091066     PISSN: 19322275     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anclin.2008.05.001     Document Type: Review

References (144)

1. D'Ancona G., Baillot R., Poirier B., et al. Determinants of gastrointestinal complications in cardiac surgery. Tex Heart Inst J 30 (2003) 280-285
2. McSweeney M., Garwood S., Levin J., et al. Adverse gastrointestinal complications after cardiopulmonary bypass: can outcome be predicted from preoperative risk factors?. Anesth Analg 98 (2004) 1610-1617
3. Zacharias A., Schwann T.A., Parenteau G.L., et al. Predictors of gastrointestinal complications in cardiac surgery. Tex Heart Inst J 27 (2000) 93-99
4. Hessel E. Abdominal organ injury after cardiac surgery. Semin Cardiothorac Vasc Anesth 8 (2004) 243-263
5. Bizouarn P., Ausseur A., Desseigne P., et al. Early and late outcome after elective cardiac surgery in patients with cirrhosis. Ann Thorac Surg 67 (1999) 1334-1338
6. Hayashida N., Shoujima T., Teshima H., et al. Clinical outcome after cardiac operations in patients with cirrhosis. Ann Thorac Surg 77 (2004) 500-505
7. Kaplan M., Cimen S., Kut M., et al. Cardiac operations for patients with chronic liver disease. Heart Surg Forum 5 (2002) 60-65
8. Klemperer J., Ko W., Krieger K., et al. Cardiac operations in patients with cirrhosis. Ann Thorac Surg 65 (1998) 85-87
9. Christenson J., Schmuziger M., Maurice J., et al. Gastrointestinal complications after coronary artery bypass grafting. J Thorac Cardiovasc Surg 108 (1994) 899-906
10. Egleston C.V., Wood A.E., Gorey T.F., et al. Gastrointestinal complications after cardiac surgery. Ann R Coll Surg Engl 75 (1993) 52-56
11. Takala J. Determinants of splanchnic blood flow. Br J Anaesth 77 (1997) 50-58
12. Lautt W.W. Control of hepatic and intestinal blood flow: effect of isovolaemic hemodilution on blood flow and oxygen uptake in the intact liver and intestines. J Physiol 265 (1977) 313-326
13. Mathie R.T. Hepatic blood flow during cardiopulmonary bypass. Crit Care Med 21 (1993) S72-S76
14. Mathie R.T., Ohri S.K., Batten J.J., et al. Hepatic blood flow during cardiopulmonary bypass operations: the effect of temperature and pulsatility. J Thorac Cardiovasc Surg 114 (1997) 292-293
15. Richardson P., and Withrington P. Intrinsic and nervous control of liver blood flow. Gastroenterology 81 (1981) 159-173
16. Ackland G., Grocott M., and Mythen M. Understanding gastrointestinal perfusion in critical care: so near and yet so far. Crit Care 4 (2000) 269-281
17. Matheson P., Wilson M., and Garrison R. Regulation of intestinal blood flow. J Surg Res 93 (2000) 182-196
18. Rao P.N., Bronsther O.L., Pinna A.D., et al. Hyaluronate levels in donor organ washout effluents: a simple and predictive parameter of graft viability. Liver 16 (1996) 48-54
19. Collins J.D., Bassendine M.F., Ferner R., et al. Incidence and prognostic importance of jaundice after cardiopulmonary bypass surgery. Lancet 1 (1983) 1119-1122
20. Reves J.G., Karp R.B., Buttner E.E., et al. Neuronal and adrenomedullary catecholamine release in response to cardiopulmonary bypass in man. Circulation 66 (1982) 49-55
21. Pearson D.T., Carter R.F., Hanmo M.B., et al. Gaseous microemboli during open heart surgery (1981), MTP, Lancaster
22. Blauth C., Cosgrove D., Webb B., et al. Atheroembolism from the ascending aorta. An emerging problem in cardiac surgery. J Thorac Cardiovasc Surg 103 (1992) 1104-1111
23. Doty J., Wilentz R., Salazar J., et al. Atheroembolism in cardiac surgery. Ann Thorac Surg 75 (2003) 1221-1226
24. Nomoto S., Shimahara Y., Kumada K., et al. Influence of hepatic mitochondrial redox state on compliment biosynthesis and activation during and after cardiopulmonary bypass operations. Eur J Cardiothorac Surg 10 (1996) 273-278
25. Gardeback M., Settergren G., Brodin L., et al. Splanchnic blood flow and oxygen uptake during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 16 (2002) 308-315
26. Iribe G., Yamada H., Matsunaga A., et al. Effects of the phosphodiesterase III inhibitors olprinone, milrinone, and amrinone on hepatosplanchnic oxygen metabolism. Crit Care Med 28 (2000) 743-748
27. Thoren A., Elam A., and Ricksten S.E. Jejunal mucosal perfusion is well maintained during mild hypothermic cardiopulmonary bypass in humans. Anesth Analg 92 (2001) 5-11
28. Andersen L.W., Landow L., Baek L., et al. Association between gastric intramucosal pH and splanchnic endotoxin, antibody to endotoxin, and tumor necrosis factor-alpha concentrations in patients undergoing cardiopulmonary bypass. Crit Care Med 21 (1993) 210-217
29. Brix-Christensen V., Petersen T.K., Ravn H.B., et al. Cardiopulmonary bypass elicits a pro- and anti-inflammatory cytokine response and impaired neutrophil chemotaxis in neonatal pigs. Acta Anaesthesiol Scand 45 (2001) 407-413
30. Laffey J.G., Boylan J.F., and Cheng D.C. The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology 97 (2002) 215-252
31. Hill G.E. The inflammatory response to cardiopulmonary bypass. Semin Cardiothorac Vasc Anesth 5 (2001) 229-235
32. Riddington D.W., Venkatesh B., Boivin C.M., et al. Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass. JAMA 275 (1996) 1007-1012
33. Chaney M.A. Corticosteroids and cardiopulmonary bypass: a review of clinical investigations. Chest 121 (2002) 921-931
34. Paparella D., Yau T.M., and Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment; an update. Eur J Cardiothorac Surg 21 (2002) 232-244
35. Hirata N., Sawa Y., and Matsuda H. Predictive value of preoperative serum cholinesterase concentration in patients with liver dysfunction undergoing cardiac surgery. J Card Surg 14 (1999) 172-177
36. Mastoraki A., Karatzis E., Mastoraki S., et al. Postoperative jaundice after cardiac surgery. Hepatobiliary Pancreat Dis Int 6 (2007) 383-387
37. Ryan T.A., Rady M.Y., Bashour C.A., et al. Predictors of outcome in cardiac surgery patients with prolonged intensive care stay. Chest 112 (1997) 1035-1042
38. Wang M., Chao A., Huang C., et al. Hyperbilirubinemia after cardiac operation. J Thorac Cardiovasc Surg 108 (1994) 429-436
39. Michalopoulos A., Alivizatos P., and Geroulanos S. Hepatic dysfunction following cardiac surgery: determinants and consequences. Hepatogastroenterology 44 (1997) 779-783
40. Raman J., Kochi K., Morimatsu H., et al. Severe ischemic early liver injury after cardiac surgery. Ann Thorac Surg 74 (2002) 1601-1606
41. Musleh G.S., Patel N.C., Grayson A.D., et al. Off-pump coronary artery bypass surgery does not reduce gastrointestinal complications. Eur J Cardiothorac Surg 23 (2003) 170-174
42. Sanisoglu I., Guden M., Bayramoglu Z., et al. Does off-pump CABG reduce gastrointestinal complications?. Ann Thorac Surg 77 (2004) 619-625
43. Velissaris T., Tang A., Murray M., et al. A prospective randomized study to evaluate splanchnic hypoxia during beating-heart and conventional coronary revascularization. Eur J Cardiothorac Surg 23 (2003) 917-924
44. Yamada T., Ochiai R., Takeda J., et al. Off-pump coronary artery bypass attenuates transient hepatocellular damage after myocardial revascularization. J Cardiothorac Vasc Anesth 19 (2005) 603-607
45. Autschbach R., Falk V., Lange H., et al. Assessment of metabolic liver function and hepatic blood flow during cardiopulmonary bypass. Thorac Cardiovasc Surg 44 (1996) 76-80
46. Huang Y.S., Lee S.D., Deng J.F., et al. Measuring lidocaine metabolite-monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. J Hepatol 19 (1993) 140-147
47. Lehmann U., Armstrong V.W., Schutz E., et al. Monoethylglycinexylidide as an early predictor of posttraumatic multiple organ failure. Ther Drug Monit 17 (1995) 125-132
48. Ascione R., Talpahewa S., Rajakaruna C., et al. Splanchnic organ injury during coronary surgery with or without cardiopulmonary bypass: a randomized, controlled trial. Ann Thorac Surg 81 (2006) 97-103
49. Kumle B., Boldt J., Suttner S., et al. Influence of prolonged cardiopulmonary bypass times on splanchnic perfusion and markers of splanchnic organ function. Ann Thorac Surg 75 (2003) 1558-1564
50. Perugini R.A., Orr R.K., Porter D., et al. Gastrointestinal complications following cardiac surgery. An analysis of 1477 cardiac surgery patients. Arch Surg 132 (1997) 352-357
51. Spotnitz W., Sanders R., Hanks J., et al. General surgical complications can be predicted after cardiopulmonary bypass. Ann Surg 221 (1995) 489-496
52. Okano N., Hiraoka H., Owada R., et al. Hepatosplanchnic oxygenation is better preserved during mild hypothermic than during normothermic cardiopulmonary bypass. Can J Anaesth 48 (2001) 1011-1014
53. Chetty G., Sharpe D.A., Nandi J., et al. Liver blood flow during cardiac surgery. Perfusion 19 (2004) 153-156
54. Fromes Y., Gaillard D., Ponzio O., et al. Reduction of the inflammatory response following coronary bypass grafting with total minimal extracorporeal circulation. Eur J Cardiothorac Surg 22 (2002) 527-533
55. Banbury M.K., Kouchoukos N.T., Allen K.B., et al. Emboli capture using the Embol-X intraaortic filter in cardiac surgery: a multicentered randomized trial of 1,289 patients. Ann Thorac Surg 76 (2003) 508-515
56. DeFoe G., Ross C., Olmstead E., et al. Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg 71 (2001) 769-776
57. Fang W., Helm R., Krieger K., et al. Impact of minimum hematocrit during cardiopulmonary bypass on mortality in patients undergoing coronary artery surgery. Circulation 96 (1997) 194-199
58. Nollert G., Sperling J., Sakamoto T., et al. Higher hematocrit improves liver blood flow and metabolism during cardiopulmonary bypass in piglets. Thorac Cardiovasc Surg 49 (2001) 226-230
59. Klein T.F., Osmer C., Muller M., et al. The effect of a pre-operative infusion of Ringer's solution on splanchnic perfusion in patients undergoing coronary artery bypass grafting. Anaesthesia 57 (2002) 756-760
60. Mythen M.G., and Webb A.R. Perioperative plasma volume expansion reduces the incidence of gut mucosal hypoperfusion during cardiac surgery. Arch Surg 130 (1995) 42-49
61. Sharpe D.A., Mitchel I.M., Kay E.A., et al. Enhancing liver blood flow after cardiopulmonary bypass: the effects of dopamine and dopexamine. Perfusion 14 (1999) 29-36
62. Bach F., Silomon M., Grundmann U., et al. Effects of dopexamine on splanchnic perfusion in cardiac surgery. Anaesthesist 48 (1999) 713-717
63. Mollhoff T., Loick H.M., van Aken H., et al. Milrinone modulates endotoxemia systemic inflammation and subsequent acute phase response after cardiopulmonary bypass. Anesthesiology 90 (1999) 72-80
64. Sakka S., Hofmann D., Thuemer O., et al. Increasing cardiac output by epinephrine after cardiac surgery: effects on indocyanine green plasma disappearance rate and splanchnic microcirculation. J Cardiothorac Vasc Anesth 21 (2007) 351-356
65. Mangano D.T., and Group MSoPIR. Aspirin and mortality from coronary bypass surgery. N Engl J Med 347 (2002) 1309-1317
66. Morariu A., Loef B., Aarts L., et al. Dexamethasone: benefit and prejudice for patients undergoing on-pump coronary artery bypass grafting. Chest 128 (2005) 2677-2687
67. An Y., and Xiao Y. The preventative role of growth hormone on acute liver injury induced by cardiopulmonary bypass in a rat model. Eur J Cardiothorac Surg 31 (2007) 1037-1043
68. Huang H., Yin R., Zhu J., et al. Protective effects of melatonin and N-acetylcysteine on hepatic injury in a rat cardiopulmonary bypass model. J Surg Res 142 (2007) 153-161
69. Conlon P.J., Stafford-Smith M., White W.D., et al. Acute renal failure following cardiac surgery. Nephrol Dial Transplant 14 (1999) 1158-1162
70. Lassnigg A., Schmidlin D., Mouhieddine M., et al. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol 15 (2004) 1597-1605
71. Ryckwaert F., Boccara G., Frappier J.M., et al. Incidence, risk factors, and prognosis of a moderate increase in plasma creatinine early after cardiac surgery. Crit Care Med 30 (2002) 1495-1498
72. Chertow G.M., Lazarus J.M., Christiansen C.L., et al. Preoperative renal risk stratification. Circulation 95 (1997) 878-884
73. Rosner M.H., and Okusa M.D. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol 1 (2006) 19-32
74. Vossler M.R., Ni H., Toy W., et al. Pre-operative renal function predicts development of chronic renal insufficiency after orthotopic heart transplantation. J Heart Lung Transplant 21 (2002) 874-881
75. Higgins T.L., Estafanous F.G., Loop F.D., et al. Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients. A clinical severity score. JAMA 267 (1992) 2344-2348
76. Aronson S., Fontes M.L., Miao Y., et al. Risk index for perioperative renal dysfunction/failure: critical dependence on pulse pressure hypertension. Circulation 115 (2007) 733-742
77. Chew S.T., Newman M.F., White W.D., et al. Preliminary report on the association of apolipoprotein E polymorphisms, with postoperative peak serum creatinine concentrations in cardiac surgical patients. Anesthesiology 93 (2000) 325-331
78. Grayson A.D., Khater M., Jackson M., et al. Valvular heart operation is an independent risk factor for acute renal failure. Ann Thorac Surg 75 (2003) 1829-1835
79. Habib R.H., Zacharias A., Schwann T.A., et al. Adverse effects of low hematocrit during cardiopulmonary bypass in the adult: should current practice be changed?. J Thorac Cardiovasc Surg 125 (2003) 1438-1450
80. Habib R.H., Zacharias A., Schwann T.A., et al. Role of hemodilutional anemia and transfusion during cardiopulmonary bypass in renal injury after coronary revascularization: implications on operative outcome. Crit Care Med 33 (2005) 1749-1756
81. Abu-Omar Y., Mussa S., Naik M.J., et al. Evaluation of Cystatin C as a marker of renal injury following on-pump and off-pump coronary surgery. Eur J Cardiothorac Surg 27 (2005) 893-898
82. Loef B.G., Epema A.H., Navis G., et al. Off-pump coronary revascularization attenuates transient renal damage compared with on-pump coronary revascularization. Chest 121 (2002) 1190-1194
83. Massoudy P., Wagner S., Thielmann M., et al. Coronary artery bypass surgery and acute kidney injury-impact of the off-pump technique. Nephrol Dial Transplant (2008) in press
84. Tang A.T., Knott J., Nanson J., et al. A prospective randomized study to evaluate the renoprotective action of beating heart coronary surgery in low risk patients. Eur J Cardiothorac Surg 22 (2002) 118-123
85. Gu Y.J., Mariani M.A., Boonstra P.W., et al. Complement activation in coronary artery bypass grafting patients without cardiopulmonary bypass: the role of tissue injury by surgical incision. Chest 116 (1999) 892-898
86. Wan S., LeClerc J.L., and Vincent J.L. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 112 (1997) 676-692
87. van Oeveren W., Jansen N.J., Bidstrup B.P., et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 44 (1987) 640-645
88. Royston D. Blood-sparing drugs: aprotinin, tranexamic acid, and epsilon-aminocaproic acid. Int Anesthesiol Clin 33 (1995) 155-179
89. Blauhut B., Gross C., Necek S., et al. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 101 (1991) 958-967
90. Cosgrove III D.M., Heric B., Lytle B.W., et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 54 (1992) 1031-1036 [discussion: 1036-8]
91. Lemmer Jr. J.H., Stanford W., Bonney S.L., et al. Aprotinin for coronary artery bypass grafting: effect on postoperative renal function. Ann Thorac Surg 59 (1995) 132-136
92. Kramer H.J., Moch T., von Sicherer L., et al. Effects of aprotinin on renal function and urinary prostaglandin excretion in conscious rats after acute salt loading. Clin Sci (Lond) 56 (1979) 547-553
93. Seto S., Kher V., Scicli A.G., et al. The effect of aprotinin (a serine protease inhibitor) on renal function and renin release. Hypertension 5 (1983) 893-899
94. Kincaid E.H., Ashburn D.A., Hoyle J.R., et al. Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery?. Ann Thorac Surg 80 (2005) 1388-1393 [discussion: 1393]
95. Mangano D.T., Tudor I.C., and Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354 (2006) 353-365
96. Karkouti K., Beattie W.S., Dattilo K.M., et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 46 (2006) 327-338
97. Shaw A.D., Stafford-Smith M., White W.D., et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 358 (2008) 784-793
98. Dietrich W., Busley R., and Boulesteix A.L. Effects of aprotinin dosage on renal function: an analysis of 8,548 cardiac surgical patients treated with different dosages of aprotinin. Anesthesiology 108 (2008) 189-198
99. Furnary A.P., Wu Y., Hiratzka L.F., et al. Aprotinin does not increase the risk of renal failure in cardiac surgery patients. Circulation 116 Suppl 1 (2007) I127-I133
100. Fergusson D.A., Hebert P.C., Mazer C.D., et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 358 (2008) 2319-2331
101. Boldt J., Brosch C., Ducke M., et al. Influence of volume therapy with a modern hydroxyethylstarch preparation on kidney function in cardiac surgery patients with compromised renal function: a comparison with human albumin. Crit Care Med 35 12 (2007) 2740-2746
102. van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 345 (2001) 1359-1367
103. Krinsley J.S. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 79 (2004) 992-1000
104. Ouattara A., Lecomte P., Le Manach Y., et al. Poor intraoperative blood glucose control is associated with a worsened hospital outcome after cardiac surgery in diabetic patients. Anesthesiology 103 (2005) 687-694
105. Furnary A.P., Gao G., Grunkemeier G.L., et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 125 (2003) 1007-1021
106. Gandhi G.Y., Nuttall G.A., Abel M.D., et al. Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial. Ann Intern Med 146 (2007) 233-243
107. MacGregor D.A., Smith T.E., Prielipp R.C., et al. Pharmacokinetics of dopamine in healthy male subjects. Anesthesiology 92 (2000) 338-346
108. Bellomo R., Chapman M., Finfer S., et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials group. Lancet 356 (2000) 2139-2143
109. Marik P.E., and Iglesias J. Low-dose dopamine does not prevent acute renal failure in patients with septic shock and oliguria. NORASEPT II study investigators. Am J Med 107 (1999) 387-390
110. Tang A.T., El-Gamel A., Keevil B., et al. The effect of 'renal-dose' dopamine on renal tubular function following cardiac surgery: assessed by measuring retinol binding protein (RBP). Eur J Cardiothorac Surg 15 (1999) 717-721 [discussion: 721-2]
111. Kellum J.A. The use of diuretics and dopamine in acute renal failure: a systematic review of the evidence. Crit Care (Lond) 1 (1997) 53-59
112. Kellum J.A., and Decker J.M. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 29 (2001) 1526-1531
113. Marik P.E. Low-dose dopamine: a systematic review. Intensive Care Med 28 (2002) 877-883
114. Davis R.F., Lappas D.G., Kirklin J.K., et al. Acute oliguria after cardiopulmonary bypass: renal functional improvement with low-dose dopamine infusion. Crit Care Med 10 (1982) 852-856
115. Mathur V.S., Swan S.K., Lambrecht L.J., et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 27 (1999) 1832-1837
116. Garwood S., Swamidoss C.P., Davis E.A., et al. A case series of low-dose fenoldopam in seventy cardiac surgical patients at increased risk of renal dysfunction. J Cardiothorac Vasc Anesth 17 (2003) 17-21
117. Haase M., Haase-Fielitz A., Bagshaw S.M., et al. Phase II, randomized, controlled trial of high-dose N-acetylcysteine in high-risk cardiac surgery patients. Crit Care Med 35 (2007) 1324-1331
118. Halpenny M., Lakshmi S., O'Donnell A., et al. Fenoldopam: renal and splanchnic effects in patients undergoing coronary artery bypass grafting. Anaesthesia 56 (2001) 953-960
119. Ranucci M., Soro G., Barzaghi N., et al. Fenoldopam prophylaxis of postoperative acute renal failure in high-risk cardiac surgery patients. Ann Thorac Surg 78 (2004) 1332-1337 [discussion: 1337-8]
120. Halpenny M., Rushe C., Breen P., et al. The effects of fenoldopam on renal function in patients undergoing elective aortic surgery. Eur J Anaesthesiol 19 (2002) 32-39
121. Bove T., Landoni G., Calabro M.G., et al. Renoprotective action of fenoldopam in high-risk patients undergoing cardiac surgery: a prospective, double-blind, randomized clinical trial. Circulation 111 (2005) 3230-3235
122. Oliver Jr. W.C., Nuttall G.A., Cherry K.J., et al. A comparison of fenoldopam with dopamine and sodium nitroprusside in patients undergoing cross-clamping of the abdominal aorta. Anesth Analg 103 (2006) 833-840
123. Stone G.W., McCullough P.A., Tumlin J.A., et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 290 (2003) 2284-2291
124. Landoni G., Biondi-Zoccai G.G., Tumlin J.A., et al. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Am J Kidney Dis 49 (2007) 56-68
125. Lassnigg A., Donner E., Grubhofer G., et al. Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol 11 (2000) 97-104
126. Ip-Yam P.C., Murphy S., Baines M., et al. Renal function and proteinuria after cardiopulmonary bypass: the effects of temperature and mannitol. Anesth Analg 78 (1994) 842-847
127. Marenzi G., Assanelli E., Marana I., et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 354 (2006) 2773-2782
128. Tepel M., van der Giet M., Schwarzfeld C., et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343 (2000) 180-184
129. Burns A., Gray P.A., Bodenham A.R., et al. Dopexamine: studies in the general intensive care unit and after liver transplantation. J Auton Pharmacol 10 Suppl 1 (1990) s109-s114
130. Sisillo E., Ceriani R., Bortone F., et al. N-acetylcysteine for prevention of acute renal failure in patients with chronic renal insufficiency undergoing cardiac surgery: a prospective, randomized, clinical trial. Crit Care Med 36 (2008) 81-86
131. Neumayer H.H., Gellert J., and Luft F.C. Calcium antagonists and renal protection. Ren Fail 15 (1993) 353-358
132. Young E.W., Diab A., and Kirsh M.M. Intravenous diltiazem and acute renal failure after cardiac operations. Ann Thorac Surg 65 (1998) 1316-1319
133. Piper S.N., Kumle B., Maleck W.H., et al. Diltiazem may preserve renal tubular integrity after cardiac surgery. Can J Anaesth 50 (2003) 285-292
134. Kunzendorf U., Walz G., Brockmoeller J., et al. Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipients. Transplantation 52 (1991) 280-284
135. Baughman K.L. B-type natriuretic peptide-a window to the heart. N Engl J Med 347 (2002) 158-159
136. Hynynen M., Tikkanen I., Salmenpera M., et al. Plasma atrial natriuretic peptide concentrations during induction of anesthesia and acute volume loading in patients undergoing cardiac surgery. J Cardiothorac Anesth 1 (1987) 401-407
137. Allgren R.L., Marbury T.C., Rahman S.N., et al. Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med 336 (1997) 828-834
138. Lewis J., Salem M.M., Chertow G.M., et al. Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney Dis 36 (2000) 767-774
139. Kelleher S.P., Robinette J.B., Miller F., et al. Effect of hemorrhagic reduction in blood pressure on recovery from acute renal failure. Kidney Int 31 (1987) 725-730
140. Mills R.M., LeJemtel T.H., Horton D.P., et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 34 (1999) 155-162
141. Colucci W.S. Nesiritide for the treatment of decompensated heart failure. J Card Fail 7 (2001) 92-100
142. Sackner-Bernstein J.D., Skopicki H.A., and Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005) 1487-1491
143. Mentzer Jr. R.M., Oz M.C., Sladen R.N., et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA Trial. J Am Coll Cardiol 49 (2007) 716-726
144. Bellomo R., Ronco C., Kellum J.A., et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8 (2004) R204-R212